Publicaciones en las que colabora con Noelia Casares Lagar (24)

2018

  1. Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in b lymphoid neoplasms

    Haematologica, Vol. 103, Núm. 6, pp. 1065-1072

2017

  1. Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor

    Oncotarget, Vol. 8, Núm. 42, pp. 71709-71724

2015

  1. Inhibition of FOXP3/NFAT interaction enhances T cell function after TCR stimulation

    Journal of Immunology, Vol. 195, Núm. 7, pp. 3180-3189

2013

  1. A fusion protein between streptavidin and the endogenous tlr4 ligand EDA targets biotinylated antigens to dendritic cells and induces t cell responses in vivo

    BioMed Research International, Vol. 2013

2012

  1. Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses

    Vaccine, Vol. 30, Núm. 18, pp. 2848-2858

  2. Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin

    International Journal of Cancer, Vol. 131, Núm. 3, pp. 641-651

2011

  1. Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection

    Journal of Hepatology, Vol. 54, Núm. 3, pp. 422-431

2010

  1. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice

    Journal of Immunology, Vol. 185, Núm. 9, pp. 5150-5159

  2. Tumor therapy in mice by using a tumor antigen linked to modulin peptides from Staphylococcus epidermidis

    Vaccine, Vol. 28, Núm. 44, pp. 7146-7154

2009

  1. Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein

    Journal of Hepatology, Vol. 51, Núm. 3, pp. 520-527

  2. Peptide inhibitors of transforming growth factor-β enhance the efficacy of antitumor immunotherapy

    International Journal of Cancer, Vol. 125, Núm. 11, pp. 2614-2623

2008

  1. In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-β1

    Journal of Immunology, Vol. 181, Núm. 1, pp. 126-135

2007

  1. The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo

    Journal of Immunology, Vol. 178, Núm. 2, pp. 748-756

  2. Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection

    Journal of Virology, Vol. 81, Núm. 7, pp. 3662-3666

2003

  1. A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine-induced liver damage

    Hepatology, Vol. 37, Núm. 2, pp. 461-470

  2. CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination

    Journal of Immunology, Vol. 171, Núm. 11, pp. 5931-5939

  3. Engineering Th determinants for efficient priming of humoral and cytotoxic T cell responses

    International Immunology, Vol. 15, Núm. 6, pp. 691-699

2002

  1. Abnormal priming of CD4+ T cells by dendritic cells expressing hepatitis C virus core and E1 proteins

    Journal of Virology, Vol. 76, Núm. 10, pp. 5062-5070

  2. Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements

    Clinical Cancer Research, Vol. 8, Núm. 7, pp. 2336-2344

  3. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus

    Vaccine, Vol. 21, Núm. 3-4, pp. 202-210